nafamostat has been researched along with B-Cell Chronic Lymphocytic Leukemia in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ijichi, S | 1 |
| Sano, Y | 1 |
| Une, F | 1 |
| Maruyama, I | 1 |
| Osame, M | 1 |
1 other study available for nafamostat and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
[Accessory use of protease-inhibiting agents for disease remission in a patient with autoimmune hemolytic anemia associated with B-CLL].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Benzamidines; Complement Activation; Complement Inactivator Pro | 1990 |